Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nictavi is a private ophthalmic medical device company focused on corneal care and eyelid-closure therapies. Its lead and apparently sole commercial product is the patented Tarsus Eyelid Patch, an FDA-listed eyelid closure device designed to help protect the ocular surface, retain moisture, and support healing in patients with conditions such as lagophthalmos, exposure-related corneal damage, and corneal epithelial defects. The company positions the patch for use across ophthalmology, optometry, pediatric eye care, surgical recovery, and hospital/ICU settings. Nictavi appears to operate as a niche medtech manufacturer and wholesaler rather than a drug-development biotech company. The business was founded by Nathan Horner based on a personal corneal disease journey and has received recognition and grant support from pediatric medtech innovation programs.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nictavi.